Bone marrow expression of vascular endothelial growth factor in myelofibrosis with myeloid metaplasia.

Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients.

Bone marrow angiogenesis and its clinical correlates in myelofibrosis with myeloid metaplasia.

Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin.

Myelofibrosis with myeloid metaplasia: new developments in pathogenesis and treatment.

Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia.

Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia.

Concomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylate.

Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment.

Effects of the MEK inhibitor CI-1040 (PD 184352) on progenitor growth from normal and myelodysplastic marrow.